Search results
Scientists report longest known ‘extreme’ Covid infection in 72-year-old man
The Independent via Yahoo News· 20 hours agoThe patient underwent stem cell transplantation to treat a pre-existing condition and a further...
Hitchhiking of synthetic antigen stimulates antibody production against cancer cells
Medical Xpress· 3 days agoThe approach gives a new direction to develop vaccine candidates for a variety of cancers, the researchers say. Inside the human body, cancer cells can weaken or shut down the production of ...
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical...
Digital Journal· 3 days agoThe platform is now integrating epitope binning into its formulas. Epitope binning is a method used to compare and categorize a collection of monoclonal antibodies that are designed to target ...
25-Year-Old Shares Subtle Lymphoma Symptoms That Were Misdiagnosed
Best Life· 12 hours agoAttributing chest pain or a stubborn cough to heartburn or a lingering cold may seem harmless—but...
Blood test may identify who is at risk for developing multiple sclerosis
UPI· 6 days agoAn early marker of multiple sclerosis could help doctors figure out who will eventually fall prey to...
Manatee County’s Roskamp Institute announces new clinic for Alzheimer’s treatment
Bradenton Herald via Yahoo News· 9 hours agoTiffany Tompkins/ttompkins@bradenton.com How Leqembi works Leqembi, produced and marketed by Biogen...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 10 hours agoModerna stock is yo-yoing after the company unveiled early-stage test results for its...
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual...
Benzinga· 15 hours agoREDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus, NASDAQ:CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8
Analyst Report: Biogen Inc.
Morningstar Research via Yahoo Finance· 9 hours agoBiogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody
OncoC4 Announces FDA Clearance of IND Application for Novel SIGLEC 10 Immune Checkpoint Inhibitor...
Morningstar· 2 days agoONC-841 is a potential first-in-class SIGLEC 10 antibody designed to block an innate and potentially adaptive immune checkpoint and prevent cancer evasion of immune cellsAnti-tumor ...
